Myeloproliferative neoplasms (MPN) are classified into chronic myeloid leukemia (CML) and Philadelphia chromosome-negative MPN (Ph-negative MPN). CML is characterized by the t(9;22)(q34;q11) translocation, resulting in the fusion protein BCR-ABL1. Ph-negative MPN are characterized by mutations in driver genes leading to activation of the JAK2-STAT5 pathway. First described in 2005, the JAK2V617F mutation is found in almost all cases of polycythemia vera and about half cases of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Mutations of *CALR* were reported in 2013 in the majority of *JAK2* no-mutated ET and PMF. The cooccurrence of both BCR-ABL1 and *JAK2* or *CALR* is very rare. Here, we describe a case of CML associated with a mutation of *CALR* detectable after 3 months of treatment by imatinib.

A 76-year-old-man with a history of hypertension, diabetes, and dyslipidemia was referred for leukocytosis. The initial blood analysis revealed (i) an elevated white blood count (73.6 10^9^/L, including 19% of myeloid immature cells and 2.3% of blast cells), (ii) a normal hemoglobin level (139 g/L) and (iii) a thrombocytosis (890 10^9^/L). The bone marrow cytology and histology showed a major granulocytic hyperplasia, megakaryocytes were numerous, normal or with small hypolobated nuclei. Of note, only 2 megacaryocytes were large with hyperlobated nuclei on the biopsy.

A molecular screening for MPN was performed and revealed a *BCR-ABL1* fusion transcript (cooccurrence of e13a2 and e14a2 transcripts). *JAK2*V617F, *CALR*, and *MPL*W515 were negative by conventional screening. Conventional cytogenetics was 46,XY,t(9;22)(q34;q11)\[20\]. A treatment by imatinib 400 mg daily was initiated leading to a normalization of leukocytes and platelets counts.

After 3 months, a reincrease of platelets count was observed (1022 10^9^/L) despite an optimal molecular response to imatinib with a ratio BCRL-ABL1/ABL1 of 0.96% (Fig. [1](#F1){ref-type="fig"}). A new molecular screening for Ph-MPN driver genes was performed and revealed a *CALR* type 1 mutation (NM_004343:c.1099_1150del) with an allele burden of 27%. A treatment by hydroxycarbamide was added and platelets decreased gradually. Nine months later, a new bone marrow biopsy was performed that showed a myeloproliferative neoplasm of the megakaryocytic lineage and a grade 1 focal fibrosis. Finally, an essential thrombocythemia (ET) associated to CML was diagnosed. Seventeen months after the diagnosis of CML, the patient was in very good response for both CML (molecular response MR4.5) and ET (complete clinicohematologic response according to the ELN consensus).[@R1] The *CALR* allele burden remained stable during the follow-up around 25% to 30% (Fig. [1](#F1){ref-type="fig"}).

![**Biological data during the clinical course of the patient.** BCR-ABL1 fusion transcript ratio was of 36.9% at diagnosis of CML while *CALR* allele burden was of 0.8% and was only detectable using digital PCR. At 3 months, BCR-ABL1 ratio decreased to 0.96% and *CALR* mutation allele burden increase to 27%. During the follow up, CML achieved a BCR-ABL1 molecular response MR4 at 1 year and MR4.5 at 15 months. The *CALR* mutation remained stable between 20% and 30% of allele burden.](hs9-2-e29-g001){#F1}

We looked again for *CALR* mutation in the initial sample using digital PCR (QuantStudio, ThermoFisher, Waltham, USA), a more sensitive technology that allow detection up to 0.01% of allele burden.[@R2] The type 1 *CALR* mutation was detected with 0.8% of allele burden (Fig. [2](#F2){ref-type="fig"}).

![**Molecular screening for CALR mutation.** Screening for *CALR* mutation was performed by fragment analysis at diagnosis of CML (panel A), and 3 months later when the thrombocytosis appeared (panel B). Digital PCR at the time of diagnosis of CML was able to detect the *CALR* type 1 mutation with a VAF of 0.8% (panel C). VAF = variant allele frequency, WT = wild-type allele.](hs9-2-e29-g002){#F2}

Cooccurrence of BCR-ABL1 and *CALR* is a very rare event with only few cases previously reported.[@R3],[@R4],[@R5],[@R6],[@R7],[@R8] In the first published case, Cabagnols et al showed that BCR-ABL1 fusion was secondary acquired in the *CALR* clone by analyzing the mutation hierarchy at clonal level. In 2 other cases, the authors concluded that BCR-ABL1 probably arises in the *CALR*-mutated clone, based on the evolution of BCR-ABL1 quantification and *CALR* allele burden.[@R4],[@R5] In another report, a *CALR* ET (or prefibrotic myelofibrosis) was diagnosed in a CML patient with complete BCR-ABL1 molecular response.[@R7] Retrospectively, the *CALR*-mutation was detected at the diagnosis of CML 14 years earlier suggesting that the 2 molecular events occurred in separates clones. In the 2 last cases, one cannot assume about the order of acquisition of the molecular events.

Here, given the antiparallel evolution of the BCR-ABL1 transcript and *CALR* allele burden, it is reasonable to assume that the 2 events occur in 2 separate clones. At diagnosis, the *CALR* mutation was present at very low allele burden, then not detectable by fragment analysis (sensitivity around 5% of allele burden) because of the higher representation of BCR-ABL clone. The tyrosine kinase inhibitor treatment (TKI) leaded to a decrease of the BCR-ABL1 clone and allowed the expansion of *CALR* clone that can explain the short time between diagnosis of CML and ET. Not surprisingly, TKI was ineffective on *CALR*-mutated clone as in previous reports.[@R3],[@R5],[@R6]

Co-occurrence of BCR-ABL1 and *JAK2*V617F mutation was also described. It can arise either in a common clone as demonstrated by clonogenic assays[@R9] or in separate clones as shown by observing the respective evolution of BCRABL1 transcript and *JAK2*V617F allele burden levels.[@R10]

The diagnosis of Ph-MPN in patients with CML is very rare. However, the persistence or appearance of an abnormal blood count during the course of the disease and despite a good molecular BCR-ABL1 response must prompt for searching JAK2V617F, *CALR*, or *MPL* mutations. Furthermore, this molecular screening for Ph-MPN should be renewed even it was done and was negative at diagnosis of CML. The present case report also suggests that *CALR* and BCR-ABL1 events can be found in separated clones.
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